Valuation: Celcuity Inc.

Market Cap 2.73B 2.49B 2.3B 2.08B 3.91B 255B 4.07B 27.82B 11B 138B 10.25B 10.03B 435B P/E 2026 *
-10.8x
P/E 2027 * -20.1x
Enterprise Value 2.73B 2.49B 2.3B 2.08B 3.91B 255B 4.07B 27.82B 11B 138B 10.25B 10.03B 435B EV / Sales 2026 *
200x
EV / Sales 2027 * 9.63x
Free-Float
89%
Yield 2026 *
-
Yield 2027 * -
1 day-4.15%
1 week-13.56%
Current month-19.57%
1 month-1.73%
3 months-40.37%
6 months-57.94%
Current year-44.26%
1 week 55.48
Extreme 55.48
64.87
1 month 55.48
Extreme 55.48
73.28
Current year 53.54
Extreme 53.54
151.02
1 year 53.54
Extreme 53.54
151.02
3 years 7.58
Extreme 7.575
151.02
5 years 4.81
Extreme 4.81
151.02
10 years 4.03
Extreme 4.03
151.02
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 2011-12-31
Chief Executive Officer 64 2011-12-31
Director of Finance/CFO 59 2017-06-30
Director TitleAgeSince
Chairman 64 2011-12-31
Director/Board Member 64 2011-12-31
Director/Board Member 67 2014-01-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/7/26 Exercice

Director

500 0.0011%
10/1/26 Free

Director

893 0.0018%
8/14/26 Free

Chief Financial Officer

26,000 0.0562%
Change 5-day change 1-year change 3-year change Capi.($)
-4.15%-13.56%-39.30%+335.05% 2.73B
-1.34%-3.09%+56.10%+68.83% 65.45B
-0.28%-3.34%+7.47%+90.15% 58.93B
+0.57%+0.66%+26.59%+87.68% 55.21B
-2.34%-3.90%+10.90%+115.97% 46.1B
+0.09%-6.08%+18.67%+25.90% 42.49B
-2.58%+0.24%+18.54%+41.28% 35.56B
-1.76%-11.56%+126.44%+649.27% 34.57B
+0.49%-0.68%+77.16%+57.93% 32.46B
-1.69%-0.79%-40.58%+382.68% 26.28B
Average -1.30%-4.42%+26.20%+185.47% 40B
Weighted average by Cap. -0.92%-3.36%+33.11%+144.75%

Financials

2026 *2027 *
Net sales 13.64M 12.44M 11.5M 10.38M 19.55M 1.27B 20.32M 139M 54.91M 688M 51.17M 50.1M 2.17B 284M 259M 239M 216M 407M 26.52B 423M 2.89B 1.14B 14.31B 1.06B 1.04B 45.2B
Net income -279M -255M -236M -213M -400M -26.11B -416M -2.85B -1.12B -14.09B -1.05B -1.03B -44.49B -147M -134M -124M -112M -211M -13.76B -219M -1.5B -593M -7.42B -552M -541M -23.44B
Net Debt - -
Projected Income Statement - Annual - Celcuity Inc.
Logo Celcuity Inc.
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
Employees
155
Date Price Change Volume
26-11-18 $55.60 -4.15% 1,011,907
26-11-17 $58.01 -4.23% 2,544,064
26-11-16 $60.57 -5.90% 730,858
26-11-13 $64.37 +0.31% 646,496
26-11-12 $64.17 -0.23% 906,767
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Celcuity Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
55.60USD
Average target price
150.85USD
Spread / Average Target
+171.31%
  1. Stock Market
  2. Stocks
  3. CELC Stock